Related references
Note: Only part of the references are listed.The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment
Lisa Lynn ten Bergen et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2020)
Biologics and Psoriasis The Beat Goes On
Hee J. Kim et al.
DERMATOLOGIC CLINICS (2019)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparatore-controlled VOYAGE 1 trial
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparatore-controlled VOYAGE 2 trial
Kristian Reich et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
New therapies for psoriasis and psoriatic arthritis
Christopher T. Ritchlin et al.
CURRENT OPINION IN RHEUMATOLOGY (2016)
T cell responses in psoriasis and psoriatic arthritis
Marco Diani et al.
AUTOIMMUNITY REVIEWS (2015)
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up
K. A. Papp et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: Results from an open-label extension study for patients from REVEAL
Kenneth Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Christopher E. M. Griffiths et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
USTEKINUMAB FOR THE TREATMENT OF PSORIASIS: REVIEW OF THREE MULTICENTER CLINICAL TRIALS
D. Farhi
DRUGS OF TODAY (2010)
Ustekinumab: Treatment of Adult Moderate-to-Severe Chronic Plaque Psoriasis
James V. Scanlon et al.
ANNALS OF PHARMACOTHERAPY (2009)
Sustained efficacy and safety of adalimumab in psoriasis treatment: A retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment
Livia Van et al.
ARCHIVES OF DERMATOLOGY (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Craig L. Leonardi et al.
LANCET (2008)
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Kim A. Papp et al.
LANCET (2008)
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
J. -H. Saurat et al.
BRITISH JOURNAL OF DERMATOLOGY (2008)
Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics
Marina Papoutsaki et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2007)
Clinical response to alimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study
Kenneth B. Gordon et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Share Paper
